Christine Blank

The new boxed warning for Xeljanz, Olumiant, and Rinvoq includes the risk of cardiovascular adverse events and cancer.

The approval marks the ninth indication for Darzalex Faspro, the only subcutaneous anti-CD38 monoclonal antibody approved to treat multiple myeloma across multiple treatment regimens.

The composition of the microbiota of the airways of people with chronic obstructive pulmonary disorder explains varying degrees of inflammation, according to a review article published recently in the Annals of Medicine.

CMS is not requiring payment for pharmacists’ testing, patient assessment, ordering/prescribing and dispensing for oral COVID-19 antiviral drugs.

University of Buffalo researchers found that men with low incomes were at greater risk of hospital readmission.

Findings show substantial variation in payer-negotiated prices and self-pay cash prices at top-performing U.S. hospitals and considerable markups on clinician-administered drugs.

Patients who are part of the Walgreen’s Prescription Savings Club can receive Semglee at up to 80% off the cash price.

The incidence of brain swelling was highest in the group of patients who received the highest doses of Aduhelm, as well as the group of patients who are carriers of the APoE gene.

Most of the patients with no immune response after the two-dose regimen responded well to a third shot.

ICER’s review indicates that Humira’s price increases are not supported by new clinical evidence.

Patients with chronic lymphocytic leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, and multiple myeloma were more likely to have a COVID-19 breakthrough infection.

Paxlovid, an at-home treatment for COVID-19, reduces illness severity, hospitalizations, and deaths among adults by 89%.

Biosimilars can save states billions of dollars annually, according to a new report from a libertarian think tank in California.

The antidepressant fluvoxamine reduced the need for hospitalization in high-risk patients, according to a new study.

Findings from a longitudinal study of nonalcoholic fatty liver disease patients show that mortality increased with fibrosis.

But groups such as Doctors Without Borders say the agreement with the Medicines Patent Pool excludes key manufacturing countries.

Industry-sponsored survey of physicians that take care of chronic liver disease patients found evidence that suggests that incidence of severe disease has increased.

Some have expressed concerns about the risk of myocarditis and unknown longer-term side effects.

Seglentis’ co-crystal formulation targets four complementary pain relief mechanisms.

A phase 3 trial of Pfizer and BioNTech’s COVID-19 vaccine booster demonstrates an efficacy rate of 95.6%.

Tecentriq is the first cancer immunotherapy available for adjuvant treatment of non-small cell lung cancer (NSCLC).

Verzenio is the first and only CDK4/6 inhibitor approved for this patient population.

Genentech is conducting phase 3 trials of gantenerumab, an anti-amyloid antibody.

Exactly how Byooviz will be priced is unclear, noted George W. Williams, M.D., a retina specialist and past president of the American Academy of Ophthalmology. The exact cost savings will help determine whether the biosimilar gains acceptance.

Gavreto treats patients with advanced lung care and Arcalyst treats patients with recurrent pericarditis.

Merck plans to seek emergency use authorization for molnupiravir as the first oral treatment for COVID-19.

Livmarli is the first drug approved for Alagille syndrome.

Liquid biopsies and new MRI technology may help clinicians monitor and stratify patients by the likelihood of whether their liver disease will worsen.

Data is being presented at the 10th Annual IDWeek Virtual Conference, September 29 to October 3.

Keytruda plus chemotherapy reduces the risk of death by 27% in patients with triple-negative breast cancer.